Table 4 Multivariate regression analyses of doctor’s consultations and hospital care reported in the long-term and follow-up surveys

Long-term survey:

Doctor’s consultation

Long-term survey:

Hospital care

First vaccination (n = 3038, reference = BNT162b2)

 Intercept

0.11

0.07

0.16

 < 0.0001

0.01

0.00

0.04

 < 0.0001

 mRNA-1273

1.16

0.89

1.50

0.2785

1.03

0.47

2.07

0.9368

 ChAdOx1

1.65

1.07

2.47

0.0189

2.16

0.72

5.28

0.1223

 Ad26.COV2-S

1.70

1.06

2.64

0.0214

1.56

0.37

4.55

0.4733

 Age

0.99

0.98

1.00

0.0281

0.99

0.97

1.01

0.1709

 Female

1.61

1.28

2.02

 < 0.0001

1.44

0.81

2.66

0.2248

 mSCQ

1.27

1.20

1.34

 < 0.0001

1.26

1.12

1.40

 < 0.0001

 Interval V-R

1.01

1.00

1.01

0.1426

1.02

1.00

1.04

0.0541

Second vaccination (n = 9351, reference = BNT162b2 + BNT162b2)

 Intercept

0.09

0.06

0.13

 < 0.0001

0.01

0.00

0.02

 < 0.0001

 mRNA-1273 + mRNA-1273

1.14

0.97

1.34

0.1164

0.87

0.52

1.39

0.5793

 ChAdOx1 + ChAdOx1

0.72

0.48

1.07

0.1130

0.78

0.25

2.17

0.6434

 ChAdOx1 + BNT162b2

0.85

0.64

1.13

0.2711

0.39

0.16

0.91

0.0380

 ChAdOx1 + mRNA-1273

0.80

0.57

1.12

0.2047

0.23

0.06

0.71

0.0160

 Age

1.00

0.99

1.0024

0.4154

1.00

0.99

1.02

0.5247

 Female

1.64

1.45

1.85

 < 0.0001

0.89

0.64

1.24

0.4714

 mSCQ

1.24

1.20

1.28

 < 0.0001

1.22

1.14

1.30

 < 0.0001

 Interval V-R

1.01

1.01

1.01

 < 0.0001

1.02

1.01

1.03

0.0005

 Interval to 2nd dose

1.00

1.00

1.01

0.2156

1.01

0.99

1.04

0.3703

Third vaccination (n = 2371, reference = PI mRNA + BNT162b2)

 Intercept

0.15

0.10

0.23

 < 0.0001

0.01

0.00

0.03

 < 0.0001

 PI mRNA + mRNA-1273

0.95

0.73

1.24

0.7316

1.12

0.54

2.33

0.7654

 PI vector + BNT162b2

1.25

0.70

2.14

0.4362

2.62

0.80

7.32

0.0825

 PI vector + mRNA-1273

0.44

0.16

1.01

0.0759

NA*

NA*

NA*

NA*

 PI mRNA/vector + BNT162b2

0.77

0.49

1.16

0.2225

1.09

0.31

3.08

0.8780

 PI mRNA/vector + mRNA-1273

0.91

0.59

1.39

0.6809

0.46

0.07

1.71

0.3125

 Age

1.00

0.99

1.00

0.2941

1.01

0.99

1.03

0.4204

 Female

1.17

0.93

1.48

0.1794

0.71

0.38

1.34

0.2852

 mSCQ

1.28

1.20

1.36

 < 0.0001

1.25

1.08

1.44

0.0018

 Interval V-R

1.02

1.01

1.04

0.0052

1.04

1.00

1.07

0.0556

Follow-up survey:

Doctor’s consultation

Follow-up survey:

Hospital care

First/Second vaccination (n = 9601, reference = BNT162b2 + BNT162b2)

 Intercept

0.22

0.16

0.30

 < 0.0001

0.02

0.01

0.07

 < 0.0001

 mRNA-1273 + mRNA-1273

1.08

0.92

1.25

0.3450

1.32

0.66

1.42

0.9261

 ChAdOx1 + ChAdOx1

0.92

0.65

1.30

0.6490

0.54

0.39

2.16

0.9160

 ChAdOx1 + BNT162b2

0.93

0.72

1.20

0.5850

0.71

0.27

1.07

0.0923

 ChAdOx1 + mRNA-1273

0.84

0.61

1.15

0.2850

0.80

0.17

1.04

0.0749

 Age

1.00

0.99

1.00

0.1550

1.00

0.99

1.01

0.5637

 Female

1.38

1.24

1.54

 < 0.0001

1.59

0.66

1.12

0.2628

 mSCQ

1.26

1.23

1.30

 < 0.0001

1.26

1.14

1.28

 < 0.0001

 Interval V-R

1.01

1.01

1.01

 < 0.0001

1.02

1.01

1.02

 < 0.0001

 Interval to 2nd dose

1.00

0.99

1.00

0.1480

1.00

0.98

1.01

0.7033

Third vaccination (n = 2304, reference = PI mRNA + BNT162b2)

 Intercept

0.34

0.25

0.47

 < 0.0001

0.01

0.01

0.03

 < 0.0001

 PI mRNA + mRNA-1273

1.04

0.84

1.29

0.7214

0.75

0.40

1.38

0.3583

 PI vector + BNT162b2

0.95

0.58

1.52

0.8358

1.14

0.32

3.11

0.8163

 PI vector + mRNA-1273

0.79

0.42

1.43

0.4563

0.96

0.15

3.40

0.9615

 PI mRNA/vector + BNT162b2

0.82

0.58

1.15

0.2562

1.58

0.69

3.32

0.2517

 PI mRNA/vector + mRNA-1273

0.87

0.62

1.21

0.4139

0.62

0.21

1.55

0.3498

 Age

1.00

0.99

1.00

0.6220

1.02

1.00

1.03

0.0843

 Female

1.18

0.98

1.42

0.0811

0.89

0.54

1.49

0.6506

 mSCQ

1.19

1.13

1.26

 < 0.0001

1.14

1.00

1.28

0.0190

 Interval V-R

1.01

1.01

1.02

0.0013

1.01

1.00

1.03

0.0392